Use: Labeled indications
- Treatment of mild to moderate heart failure in adults.
- Increasing myocardial contractility in pediatric patients with heart failure.
- Control of resting ventricular rate in adults with chronic atrial fibrillation.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE LANOXIN is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. (1.1) Increasing myocardial contractility in pediatric patients with heart failure. (1.2) Control of resting ventricular rate in adults with chronic atrial fibrillation. (1.3) 1.1 Heart Failure in Adults LANOXIN is indicated for the treatment of mild to moderate heart failure in adults.
LANOXIN increases left ventricular ejection fraction and improves heart failure symptoms, as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, LANOXIN should be used in combination with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor. 1.2 Heart Failure in Pediatric Patients LANOXIN increases myocardial contractility in pediatric patients with heart failure. 1.3 Atrial Fibrillation in Adults LANOXIN is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation.
Contraindications
4 CONTRAINDICATIONS LANOXIN is contraindicated in patients with: Ventricular fibrillation [see Warnings and Precautions (5.1)] Known hypersensitivity to digoxin (reactions seen include unexplained rash, swelling of the mouth, lips or throat or a difficulty in breathing). A hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin. Ventricular fibrillation. (4) Known hypersensitivity to digoxin or other forms of digitalis. (4)
US FDA labelDosing: Adult
LANOXIN dose is based on patient-specific factors (age, lean body weight, renal function, etc.). See full prescribing information. Monitor for toxicity and therapeutic effect. (2) Intravenous administration is preferable to intramuscular. Avoid bolus administration. (2)
2.1 Important Dosing and Administration Information
2.1 Important Dosing and Administration Information In selecting a LANOXIN dosing regimen, it is important to consider factors that affect digoxin blood levels (e.g., body weight, age, renal function, concomitant drugs) since toxic levels of digoxin are only slightly higher than therapeutic levels. Dosing can be either initiated with a loading dose followed by maintenance dosing if rapid titration is desired or initiated with maintenance dosing without a loading dose.
Parenteral administration of digoxin should be used only when the need for rapid digitalization is urgent or when the drug cannot be taken orally. Intramuscular injection can lead to severe pain at the injection site, thus intravenous administration is preferred. If the drug must be administered by the intramuscular route, it should be injected deep into the muscle followed by massage.
For adults, no more than 500 mcg of LANOXIN Injection should be injected into a single site. For pediatric patients, no more than 200 mcg of LANOXIN Injection Pediatric should be injected into a single site. Administer the dose over a period of 5 minutes or longer and avoid bolus administration to prevent systemic and coronary vasoconstriction.
Mixing of LANOXIN Injection and Injection Pediatric with other drugs in the same container or simultaneous administration in the same intravenous line is not recommended. LANOXIN Injection and Injection Pediatric can be administered undiluted or diluted with a 4-fold or greater volume of Sterile Water for Injection, 0.9% Sodium Chloride Injection, or 5% Dextrose Injection.
The use of less than a 4-fold volume of diluent could lead to precipitation of the digoxin. Immediate use of the diluted product is recommended. Consider interruption or reduction in LANOXIN dose prior to electrical cardioversion [see Warnings and Precautions (5.4)]. Discard unused portion of LANOXIN Injection and LANOXIN Injection Pediatric.
2.2 Loading Dosing Regimen in Adults and Pediatric Patients
2.2 Loading Dosing Regimen in Adults and Pediatric Patients Table 1. Recommended LANOXIN Injection Loading Dose mcg = microgram Age Total IV Loading Dose (mcg/kg) Administer half the total loading dose initially, then ¼ the loading dose every 6-8 hours twice Premature 15-25 Full-Term 20-30 1-24 Months 30-50 2-5 Years 25-35 5-10 Years 15-30 Adults and pediatric patients over 10 years 8-12
2.3 Maintenance Dosing in Adults and Pediatric Patients Over 10 Years Old
2.3 Maintenance Dosing in Adults and Pediatric Patients Over 10 Years Old The maintenance dose is based on lean body weight, renal function, age, and concomitant products [see Clinical Pharmacology (12.3)]. The recommended starting maintenance doses in adults and pediatric patients over 10 years old with normal renal function are given in Table 2.
Doses may be increased every 2 weeks according to clinical response, serum drug levels, and toxicity. Table 2. Recommended Starting LANOXIN Injection Maintenance Dosage in Adults and Pediatric Patients Over 10 Years Old mcg = microgram Age Total Intravenous Maintenance Dose, mcg/kg/day (given once daily) Adults and pediatric patients over 10 years 2.4-3.6 Table 3 provides the recommended (once daily) maintenance dose for adults and pediatric patients over 10 years old (to be given once daily) according to lean body weight and renal function.
The doses are based on studies in adult patients with heart failure. Alternatively, the maintenance dose may be estimated by the following formula (peak body stores lost each day through elimination): Total Maintenance Dose = Loading Dose (i.e., Peak Body Stores) x % Daily Loss/100 (% Daily Loss = 14 + Creatinine clearance/5) Reduce the dose of LANOXIN in patients whose lean weight is an abnormally small fraction of their total body mass because of obesity or edema.
Table 3. Recommended Maintenance Dose (in micrograms given once daily) of LANOXIN Injection in Pediatric Patients Over 10 Years Old and Adults by Lean Body Weight and by Renal Function a For adults, creatinine clearance was corrected to 70-kg body weight or 1.73 m² body surface area. If only serum creatinine concentrations (Scr) are available, a corrected Ccr may be estimated in men as (140 – Age)/Scr.
For women, this result should be multiplied by 0.85. For pediatric patients, the modified Schwartz equation may be used. The formula is based on height in cm and Scr in mg/dL where k is a constant. Ccr is corrected to 1.73 m² body surface area. During the first year of life, the value of k is 0.33 for pre-term babies and 0.45 for term infants.
The k is 0.55 for pediatric patients and adolescent girls and 0.7 for adolescent boys. GFR (mL/min/1.73 m²) = (k x Height)/Scr b If no loading dose administered c The doses listed assume average body composition. Corrected Creatinine Clearance a Lean Body Weight c Number of Days Before Steady State Achieved b kg 40 50 60 70 80 90 100 10 mL/min 64 80 96 112 128 144 160 19 20 mL/min 72 90 108 126 144 162 180 16 30 mL/min 80 100 120 140 160 180 200 14 40 mL/min 88 110 132 154 176 198 220 13 50 mL/min 96 120 144 168 192 216 240 12 60 mL/min 104 130 156 182 208 234 260 11 70 mL/min 112 140 168 196 224 252 280 10 80 mL/min 120 150 180 210 240 270 300 9 90 mL/min 128 160 192 224 256 288 320 8 100 mL/min 136 170 204 238 272 306 340 7
2.4 Maintenance Dosing in Pediatric Patients Less Than 10 Years Old
2.4 Maintenance Dosing in Pediatric Patients Less Than 10 Years Old The starting maintenance dose for heart failure in pediatric patients less than 10 years old is based on lean body weight, renal function, age, and concomitant products [see Clinical Pharmacology (12.3)]. The recommended starting maintenance doses for pediatric patients are given in Table 4.
These recommendations assume the presence of normal renal function. Table 4. Recommended Starting LANOXIN Injection Maintenance Dosage in Pediatric Patients Less Than 10 Years Old mcg = microgram Age Dose Regimen, mcg/kg/dose (given TWICE daily) Premature 1.9-3.1 Full-Term 3-4.5 1-24 Months 4.5-7.5 2-5 Years 3.8-5.3 5-10 Years 2.3-4.5 Table 5 provides average daily maintenance dose requirements for pediatric patients less than 10 years old (to be given twice daily) with heart failure based on age, lean body weight, and renal function.
Table 5. Recommended Maintenance Dose (in micrograms given TWICE daily) of LANOXIN Injection in Pediatric Patients Less Than 10 Years of Age a Based upon Lean Body Weight and Renal Function a a Recommended are doses to be given twice daily. b The modified Schwartz equation may be used to estimate creatinine clearance. See footnote a under Table 3. c If no loading dose administered.
Corrected Creatinine Clearance b Lean Body Weight Number of Days Before Steady State Achieved c kg 5 10 20 30 40 50 60 10 mL/min 8 16 32 48 64 80 96 19 20 mL/min 9 18 36 54 72 90 108 16 30 mL/min 10 20 40 60 80 100 120 14 40 mL/min 11 22 44 66 88 110 132 13 50 mL/min 12 24 48 72 96 120 144 12 60 mL/min 13 26 52 78 104 130 156 11 70 mL/min 14 28 56 84 112 140 168 10 80 mL/min 15 30 60 90 120 150 180 9 90 mL/min 16 32 64 96 128 160 192 8 100 mL/min 17 34 68 102 136 170 204 7
2.5 Monitoring
2.5 Monitoring to Assess Safety, Efficacy, and Therapeutic Blood Levels Monitor for signs and symptoms of digoxin toxicity and clinical response. Adjust dose based on toxicity, efficacy, and blood levels. Serum digoxin levels less than 0.5 ng/mL have been associated with diminished efficacy, while levels above 2 ng/mL have been associated with increased toxicity without increased benefit.
Interpret the serum digoxin concentration in the overall clinical context, and do not use an isolated measurement of serum digoxin concentration as the basis for increasing or decreasing the LANOXIN dose. Serum digoxin concentrations may be falsely elevated by endogenous digoxin-like substances [see Drug Interactions (7.4)].
If the assay is sensitive to these substances, consider obtaining a baseline digoxin level before starting LANOXIN and correct post-treatment values by the reported baseline level. Obtain serum digoxin concentrations just before the next scheduled LANOXIN dose or at least 6 hours after the last dose. The digoxin concentration is likely to be 10-25% lower when sampled right before the next dose (24 hours after dosing) compared to sampling 8 hours after dosing (using once-daily dosing).
However, there will be only minor differences in digoxin concentrations using twice daily dosing whether sampling is done at 8 or 12 hours after a dose.
2.6 Switching from Intravenous
2.6 Switching from Intravenous Digoxin to Oral Digoxin When switching from intravenous to oral digoxin formulations, make allowances for differences in bioavailability when calculating maintenance dosages (see Table 6). Table 6. Comparison of the Systemic Availability and Equivalent Doses of Oral and Intravenous LANOXIN Absolute Bioavailability Equivalent Doses (mcg) LANOXIN Tablets 60-80% 62.5 125 250 500 LANOXIN Intravenous Injection 100% 50 100 200 400
Dosing: Altered kidney function
8.6 Renal Impairment The clearance of digoxin can be primarily correlated with the renal function as indicated by creatinine clearance. Table 3 and Table 5 provide the usual daily maintenance dose requirements for digoxin based on creatinine clearance [see Dosage and Administration (2.3)]. Digoxin is primarily excreted by the kidneys; therefore, patients with impaired renal function require smaller than usual maintenance doses of digoxin [see Dosage and Administration (2.3)].
Because of the prolonged elimination half-life, a longer period of time is required to achieve an initial or new steady-state serum concentration in patients with renal impairment than in patients with normal renal function. If appropriate care is not taken to reduce the dose of digoxin, such patients are at high risk for toxicity, and toxic effects will last longer in such patients than in patients with normal renal function.
Renal Impairment: Since the clearance of digoxin correlates with creatinine clearance, patients with renal impairment generally demonstrate prolonged digoxin elimination half-lives and greater exposures to digoxin. Therefore, titrate carefully in these patients based on clinical response and based on monitoring of serum digoxin concentrations, as appropriate.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Hepatic Impairment Plasma digoxin concentrations in patients with acute hepatitis generally fall within the range of profiles in a group of healthy subjects.
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of LANOXIN in the control of ventricular rate in children with atrial fibrillation have not been established. The safety and effectiveness of LANOXIN in the treatment of heart failure in children have not been established in adequate and well-controlled studies. However, in published literature of children with heart failure of various etiologies (e.g., ventricular septal defects, anthracycline toxicity, patent ductus arteriosus), treatment with digoxin has been associated with improvements in hemodynamic parameters and in clinical signs and symptoms.
Newborn infants display considerable variability in their tolerance to digoxin. Premature and immature infants are particularly sensitive to the effects of digoxin, and the dosage of the drug must not only be reduced but must be individualized according to their degree of maturity.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use The majority of clinical experience gained with digoxin has been in the elderly population. This experience has not identified differences in response or adverse effects between the elderly and younger patients. However, this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, which should be based on renal function, and it may be useful to monitor renal function [see Dosage and Administration (2.1)].
Administration
2.1 Important Dosing and Administration Information In selecting a LANOXIN dosing regimen, it is important to consider factors that affect digoxin blood levels (e.g., body weight, age, renal function, concomitant drugs) since toxic levels of digoxin are only slightly higher than therapeutic levels. Dosing can be either initiated with a loading dose followed by maintenance dosing if rapid titration is desired or initiated with maintenance dosing without a loading dose. Parenteral administration of digoxin should be used only when the need for rapid digitalization is urgent or when the drug cannot be taken orally. Intramuscular injection can lead to severe pain at the injection site, thus intravenous administration is preferred. If the drug must be administered by the intramuscular route, it should be injected deep into the muscle followed by massage. For adults, no more than 500 mcg of LANOXIN Injection should be injected into a single site. For pediatric patients, no more than 200 mcg of LANOXIN Injection Pediatric should be injected into a single site. Administer the dose over a period of 5 minutes or longer and avoid bolus administration to prevent systemic and coronary vasoconstriction. Mixing of LANOXIN Injection and Injection Pediatric with other drugs in the same container or simultaneous administration in the same intravenous line is not recommended. LANOXIN Injection and Injection Pediatric can be administered undiluted or diluted with a 4-fold or greater volume of Sterile Water for Injection, 0.9% Sodium Chloride Injection, or 5% Dextrose Injection. The use of less than a 4-fold volume of diluent could lead to precipitation of the digoxin. Immediate use of the diluted product is recommended. Consider interruption or reduction in LANOXIN dose prior to electrical cardioversion [see Warnings and Precautions ( 5.4 )]. Discard unused portion of LANOXIN Injection and LANOXIN Injection Pediatric.
US FDA labelDosage forms
Philippines
- Solution for injection: 250 mcg/mL
- Tablet: 250 mcg
- ) solution for injection: 250 mcg/mL (500 mcg/2 mL
- Elixir: 50 mcg/mL
Registered products in the Philippines
22 products registered with the Food and Drug Administration (FDA) Philippines list Digoxin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products22
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AccexinDigoxin | 250 mcg/mL Solution for Injection (IM/IV)Type I Clear Glass Ampoule x 2 mL (Box of 5's) | Rx | Maxitech Pharma (Pvt) Ltd.Pakistan | Accesspoint International Trading Inc. | DRP-17520 | Jan 16, 2031 | |
CardioxinDigoxin | 250 mcg/mL Solution for injection (I.V.)Amber Glass Ampoule x 2 mL (Box of 10's and 100's) | Rx | Ciron Drugs & Pharmaceuticals Pvt., Ltd.India | Phil Pharmawealth Inc. | DR-XY33472 | Jun 8, 2027 | |
CardoxinDigoxin | 250 mcg TabletAlu/Clear PVC blister pack x 10's (Box of 100's) | Rx | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-13622 | Mar 21, 2028 | |
CoxinDigoxin | 250 mcg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Unicure Remedies PVT. LTD.India | TGP Pharma Inc.Importer: Next Chemical Enterprises | DRP-6415-01 | Oct 30, 2031 | |
CoxinDigoxin | 250 mcg/mL Solution for Injection (IM/IV)Clear Glass Ampoule with Snap Off Label x 2 mL (Box of 10's) | Rx | Samarth Life Science Pvt. LtdIndia | Triple Tact Import & Export Corp.Importer: Next Chemical Enterprises | DRP-8443-01 | Aug 15, 2031 | |
DicoreDigoxin | 250 mcg/mL Solution for Injection (IM/IV)Clear Glass Ampoule with Snap off Label x 2 mL (Box of 10's) | Rx | Samarth Life Science Pvt. Ltd.India | Greencore Pharma, Inc.Importer: Next Chemical Enterprises | DRP-8443-02 | Aug 15, 2031 | |
DigamexDigoxin | 250 mcg/mL (500 mcg/2 mL) Solution for Injection (IM/IV)USP Type I clear glass ampoule x 2 mL in PVC plastic tray (Box of 10's) | Rx | Ratnaris Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-17192 | Oct 17, 2030 | |
DigosaphDigoxin | 250 mcg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Genom Biotech Pvt. Ltd.India | Ollen Pharma Trading | DRP-10971 | Jan 23, 2031 | |
DigoxDigoxin | 250 mcg TabletAlu-Alu Foil Strip x 10's (Box of 100's) | Rx | Hizon Laboratories, Inc.Philippines | Willore Pharma Corporation | DRP-2423 | Aug 31, 2031 | |
DigoxareDigoxin | 250 mcg/mL Solution for Injection (I.V.)2 mL Type I Clear Amber Glass Ampoule (Box of 6's) | Rx | Anfarm Hellas S.A.Greece | Neo-Care PhilippinesImporter: Ambicare Pharmaceuticals Inc. | DRP-7830-01 | Apr 20, 2028 | |
DigoxSaveDigoxin | 250 mcg /mL Solution for Injection (IM/IV)Type I Clear Glass ampoule x 2 mL (Box of 5's) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Savelink Pharma and Trading Co.,Importer: Accesspoint International Trading Inc. | DRP-17520-01 | Jan 16, 2031 | |
DixinDigoxin | 250 mcg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Unicure Remedies Pvt. Ltd.India | Next Chemical Enterprises | DRP-6415 | Jul 7, 2031 | |
DixinDigoxin | 250 mcg/mL Solution for Injection (IM/IV)Clear Glass Ampoule with Snap Off Label x 2 mL (Box of 10's) | Rx | Samarth Life Sciences Pvt. Ltd. (Unit Ii)India | Next Chemical Enterprises | DRP-8443 | Aug 15, 2031 | |
DoxitomDigoxin | 250mcg/mL Solution for Injection (IM/IV)Amber USP type I glass ampoule in PVC tray x 2mL (net content) (Box of 10's) | Rx | Pharmax India Private LimitedIndia | Wellchem Pharmaceutical Products | DRP-16860 | Jul 30, 2030 | |
FargoxinDigoxin | 250 mcg/mL (500 mcg/2 mL) Solution for Injection (I.M/I.V.)Type I clear colorless borosilicate glass ampoule x 2 mL (Box of 5's) | Rx | PT. Pratapa NirmalaIndonesia | Exa Life Care Pharma Inc. | DRP-9997 | Jul 2, 2036 | |
InoxinDigoxin | 250 mcg TabletAluminum Foil Strip x 10’s (Box of 100’s) | Rx | Hizon Laboratories, Inc.Philippines | Trader: Pharmaspec N.A., Inc. | DR-XY38165 | Jul 5, 2031 | |
LanoxinDigoxin | 250 mcg TabletType III Amber Glass Bottle with LDPE Snap-Fit Cap x 500's (Box of 1's) | Rx | Aspen Bad Oldesloe GmBHGermany | Importer: Aspen Philippines Inc. | DR-263 | May 16, 2027 | |
LanoxinDigoxin | 250 mcg TabletAlu/White Opaque PVC Blister Pack x10's (Box of 300's) | Rx | Aspen Bad Oldesloe GmbHGermany | Aspen Philippine Inc. | DR-XY48823 | Jul 28, 2028 | |
LanoxinDigoxin | 250 mcg/mL (500 mcg/2mL) Solution For InjectionUSP Type I clear glass ampoule x 2 mL (Box of 5's) | Rx | CenexiFrance | Importer: Aspen Philippines Inc. | DR-XY48506 | Nov 28, 2027 | |
LanoxinDigoxin | 50 mcg/mL Elixir (Pediatric/Geriatric)Clear amber glass bottle with HDPE child - resistant closure (with dropper) x 60 mL | Rx | Aspen Bad Oldesloe GmbHGermany | Aspen Philippines, Inc. | DR-262 | Sep 16, 2027 | |
LigoxinDigoxin | 250 mcg/mL Solution for Injection (I.V.)2 mL Type I Clear Amber Glass Ampoule (Box of 6's) | Rx | Anfarm Hellas S.A.Greece | Sonchel Pharma DistributorsImporter: Ambicare Pharmaceuticals Inc. | DRP-7830 | Apr 20, 2028 | |
SaphnoxinDigoxin | 250 mcg/mL (500 mcg/2 mL) Solution For InjectionUSP Type I Glass Amber colored Glass Ampoule with PVC Tray x 2 mL (Box of 5's, 6's and 10's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-14168 | Jul 18, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS LANOXIN Injection: 500 mcg/2 mL (250 mcg/mL) single-dose ampule. LANOXIN Injection: 500 mcg/2 mL (250 mcg/ mL) single-dose vial. LANOXIN Injection Pediatric: 100 mcg/mL single-dose ampule. LANOXIN Injection Pediatric: 100 mcg/mL single-dose vial. LANOXIN ® Injection: 500 mcg/2 mL (250 mcg/mL) single-dose ampule (3) LANOXIN ® Injection:500 mcg/2 mL (250 mcg/mL) single-dose vial (3) LANOXIN ® Injection Pediatric: 100 mcg/mL single-dose ampule (3) LANOXIN ® Injection Pediatric: 100 mcg/mL single-dose vial (3)
Warnings/Precautions
- Risk of rapid ventricular response leading to ventricular fibrillation in patients with AV accessory pathway. (5.1)
- Risk of advanced or complete heart block in patients with sinus node disease and AV block. (5.2)
- Digoxin toxicity: Indicated by nausea, vomiting, visual disturbances, and cardiac arrhythmias. Advanced age, low body weight, impaired renal function and electrolyte abnormalities predispose to toxicity. (5.3)
- Risk of ventricular arrhythmias during electrical cardioversion. (5.4)
- Not recommended in patients with acute myocardial infarction (5.5)
- Avoid LANOXIN in patients with myocarditis. (5.6)
5.1 Ventricular Fibrillation in Patients With Accessory AV Pathway (Wolff-Parkinson-White…
5.1 Ventricular Fibrillation in Patients With Accessory AV Pathway (Wolff-Parkinson-White Syndrome) Patients with Wolff-Parkinson-White syndrome who develop atrial fibrillation are at high risk of ventricular fibrillation. Treatment of these patients with digoxin leads to greater slowing of conduction in the atrioventricular node than in accessory pathways, and the risks of rapid ventricular response leading to ventricular fibrillation are thereby increased.
5.2 Sinus Bradycardia and Sino-atrial Block
5.2 Sinus Bradycardia and Sino-atrial Block LANOXIN may cause severe sinus bradycardia or sinoatrial block particularly in patients with pre-existing sinus node disease and may cause advanced or complete heart block in patients with pre-existing incomplete AV block. Consider insertion of a pacemaker before treatment with digoxin.
5.3 Digoxin Toxicity
5.3 Digoxin Toxicity Signs and symptoms of digoxin toxicity include anorexia, nausea, vomiting, visual changes and cardiac arrhythmias [first-degree, second-degree (Wenckebach), or third-degree heart block (including asystole); atrial tachycardia with block; AV dissociation; accelerated junctional (nodal) rhythm; unifocal or multiform ventricular premature contractions (especially bigeminy or trigeminy); ventricular tachycardia; and ventricular fibrillation]. Toxicity is usually associated with digoxin levels greater than 2 ng/mL although symptoms may also occur at lower levels.
Low body weight, advanced age or impaired renal function, hypokalemia, hypercalcemia, or hypomagnesemia may predispose to digoxin toxicity. Obtain serum digoxin levels in patients with signs or symptoms of digoxin therapy and interrupt or adjust dose if necessary [see Adverse Reactions (6) and Overdosage (10)]. Assess serum electrolytes and renal function periodically.
The earliest and most frequent manifestation of digoxin toxicity in infants and children is the appearance of cardiac arrhythmias, including sinus bradycardia. In children, the use of digoxin may produce any arrhythmia. The most common are conduction disturbances or supraventricular tachyarrhythmias, such as atrial tachycardia (with or without block) and junctional (nodal) tachycardia.
Ventricular arrhythmias are less common. Sinus bradycardia may be a sign of impending digoxin intoxication, especially in infants, even in the absence of first-degree heart block. Any arrhythmias or alteration in cardiac conduction that develops in a child taking digoxin should initially be assumed to be a consequence of digoxin intoxication.
Given that adult patients with heart failure have some symptoms in common with digoxin toxicity, it may be difficult to distinguish digoxin toxicity from heart failure. Misidentification of their etiology might lead the clinician to continue or increase LANOXIN dosing, when dosing should actually be suspended. When the etiology of these signs and symptoms is not clear, measure serum digoxin levels.
5.4 Risk of Ventricular Arrhythmias During Electrical Cardioversion
5.4 Risk of Ventricular Arrhythmias During Electrical Cardioversion It may be desirable to reduce the dose of or discontinue LANOXIN for 1-2 days prior to electrical cardioversion of atrial fibrillation to avoid the induction of ventricular arrhythmias, but physicians must consider the consequences of increasing the ventricular response if digoxin is decreased or withdrawn. If digitalis toxicity is suspected, elective cardioversion should be delayed.
If it is not prudent to delay cardioversion, the lowest possible energy level should be selected to avoid provoking ventricular arrhythmias.
5.5 Risk of Ischemia in Patients With Acute Myocardial Infarction
5.5 Risk of Ischemia in Patients With Acute Myocardial Infarction LANOXIN is not recommended in patients with acute myocardial infarction because digoxin may increase myocardial oxygen demand and lead to ischemia.
5.6 Vasoconstriction In Patients With Myocarditis
5.6 Vasoconstriction In Patients With Myocarditis LANOXIN can precipitate vasoconstriction and may promote production of pro-inflammatory cytokines; therefore, avoid use in patients with myocarditis.
5.7 Decreased Cardiac Output in Patients With Preserved Left Ventricular Systolic Function
5.7 Decreased Cardiac Output in Patients With Preserved Left Ventricular Systolic Function Patients with heart failure associated with preserved left ventricular ejection fraction may experience decreased cardiac output with use of LANOXIN. Such disorders include restrictive cardiomyopathy, constrictive pericarditis, amyloid heart disease, and acute cor pulmonale.
Patients with idiopathic hypertrophic subaortic stenosis may have worsening of the outflow obstruction due to the inotropic effects of digoxin. Patients with amyloid heart disease may be more susceptible to digoxin toxicity at therapeutic levels because of an increased binding of digoxin to extracellular amyloid fibrils.
LANOXIN should generally be avoided in these patients, although it has been used for ventricular rate control in the subgroup of patients with atrial fibrillation.
5.8 Reduced Efficacy
5.8 Reduced Efficacy In Patients With Hypocalcemia Hypocalcemia can nullify the effects of digoxin in humans; thus, digoxin may be ineffective until serum calcium is restored to normal. These interactions are related to the fact that digoxin affects contractility and excitability of the heart in a manner similar to that of calcium.
5.9 Altered Response in Thyroid Disorders and Hypermetabolic States
5.9 Altered Response in Thyroid Disorders and Hypermetabolic States Hypothyroidism may reduce the requirements for digoxin. Heart failure and/or atrial arrhythmias resulting from hypermetabolic or hyperdynamic states (e.g., hyperthyroidism, hypoxia, or arteriovenous shunt) are best treated by addressing the underlying condition.
Atrial arrhythmias associated with hypermetabolic states are particularly resistant to digoxin treatment. Patients with beri beri heart disease may fail to respond adequately to digoxin if the underlying thiamine deficiency is not treated concomitantly.
Drug interactions
- Digoxin has a narrow therapeutic index, increased monitoring of serum digoxin concentrations and for potential signs and symptoms of clinical toxicity is necessary when initiating, adjusting, or discontinuing drugs that may interact with digoxin. Prescribers should consult the prescribing information of any drug which is co-prescribed with digoxin for potential drug interaction information. PGP Inducers/Inhibitors: Drugs that induce or inhibit PGP have the potential to alter digoxin pharmacokinetics. (7.1)
- The potential for drug-drug interactions must be considered prior to and during drug therapy. See full prescribing information. (7.2, 7.3, 12.3)
7.1 P-Glycoprotein (PGP) Inducers/Inhibitors
7.1 P-Glycoprotein (PGP) Inducers/Inhibitors Digoxin is a substrate of P-glycoprotein, at the level of intestinal absorption, renal tubular section and biliary-intestinal secretion. Therefore, drugs that induce/ inhibit P-glycoprotein have the potential to alter digoxin pharmacokinetics.
7.2 Pharmacokinetic Drug Interactions
7.2 Pharmacokinetic Drug Interactions Pharmacokinetic interactions have been observed and reported primarily when digoxin is co-administered by oral route. There are very few studies that have evaluated the drug interaction when digoxin is administered via IV route. The magnitude of digoxin exposure change through IV route is generally lower than that through oral route.
Table below provides available interaction data using digoxin IV formulation (NA means not available). Digoxin concentrations increased greater than 50% Digoxin Serum Concentration Increase Digoxin AUC Increase Recommendations Quinidine NA 54-83% Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing dose by approximately 30-50% or by modifying the dosing frequency and continue monitoring.
Ritonavir NA 86% Digoxin concentrations increased less than 50% Amiodarone 17% 40% Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing frequency and continue monitoring. Propafenone 28% 29% Quinine NA 34-38% Spironolactone NA 44% Verapamil NA 24% Mirabegron 29% 27%
7.3 Potentially Significant Pharmacodynamic Drug Interactions
7.3 Potentially Significant Pharmacodynamic Drug Interactions Because of considerable variability of pharmacodynamic interactions, the dosage of digoxin should be individualized when patients receive these medications concurrently. Drugs that Affect Renal Function A decline in GFR or tubular secretion, as from ACE inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs [NSAIDs], COX-2 inhibitors may impair the excretion of digoxin.
Antiarrthymics Dofetilide Concomitant administration with digoxin was associated with a higher rate of torsades de pointes. Sotalol Proarrhythmic events were more common in patients receiving sotalol and digoxin than on either alone; it is not clear whether this represents an interaction or is related to the presence of CHF, a known risk factor for proarrhythmia, in patients receiving digoxin.
Dronedarone Sudden death was more common in patients receiving digoxin with dronedarone than on either alone; it is not clear whether this represents an interaction or is related to the presence of advanced heart disease, a known risk factor for sudden death in patients receiving digoxin. Parathyroid Hormone Analog Teriparatide Sporadic case reports have suggested that hypercalcemia may predispose patients to digitalis toxicity.
Teriparatide transiently increases serum calcium. Thyroid supplement Thyroid Treatment of hypothyroidism in patients taking digoxin may increase the dose requirements of digoxin. Sympathomimetics Epinephrine Norepinephrine Dopamine Can increase the risk of cardiac arrhythmias. Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells, causing arrhythmias in patients taking digoxin.
Supplements Calcium If administered rapidly by intravenous route, can produce serious arrhythmias in digitalized patients. Beta-adrenergic blockers and calcium channel blockers Additive effects on AV node conduction can result in bradycardia and advanced or complete heart block. Ivabradine Can increase the risk of bradycardia.
7.4 Drug/Laboratory Test Interactions
7.4 Drug/Laboratory Test Interactions Endogenous substances of unknown composition (digoxin-like immunoreactive substances [DLIS]) can interfere with standard radioimmunoassays for digoxin. The interference most often causes results to be falsely positive or falsely elevated, but sometimes it causes results to be falsely reduced.
Some assays are more subject to these failings than others. Several LC/MS/MS methods are available that may provide less susceptibility to DLIS interference. DLIS are present in up to half of all neonates and in varying percentages of pregnant women, patients with hypertrophic cardiomyopathy, patients with renal or hepatic dysfunction, and other patients who are volume-expanded for any reason.
The measured levels of DLIS (as digoxin equivalents) are usually low (0.2-0.4 ng/mL), but sometimes they reach levels that would be considered therapeutic or even toxic. In some assays, spironolactone, canrenone, and potassium canrenoate may be falsely detected as digoxin, at levels up to 0.5 ng/mL. Some traditional Chinese and Ayurvedic medicine substances like Chan Su, Siberian Ginseng, Asian Ginseng, Ashwagandha, or Danshen can cause similar interference.
Spironolactone and DLIS are much more extensively protein-bound than digoxin. As a result, assays of free digoxin levels in protein-free ultrafiltrate (which tend to be about 25% less than total levels, consistent with the usual extent of protein binding) are less affected by spironolactone or DLIS. It should be noted that ultrafiltration does not solve all interference problems with alternative medicines.
The use of an LC/MS/MS method may be the better option according to the good results it provides, especially in terms of specificity and limit of quantization.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
( 7.2 , 7.3 , 12.3 ) 7.1 P-Glycoprotein (PGP) Inducers/Inhibitors Digoxin is a substrate of P-glycoprotein, at the level of intestinal absorption, renal tubular section and biliary-intestinal secretion.
Therefore, drugs that induce/ inhibit P-glycoprotein have the potential to alter digoxin pharmacokinetics. 7.2 Pharmacokinetic Drug Interactions Pharmacokinetic interactions have been observed and reported primarily when digoxin is co-administered by oral route.
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following adverse reactions are included in more detail in the Warnings and Precautions section of the label: Cardiac arrhythmias [see Warnings and Precautions (5.1, 5.2)] Digoxin Toxicity [see Warnings and Precautions (5.3)] The overall incidence of adverse reactions with digoxin has been reported as 5-20%, with 15-20% of adverse events considered serious. Cardiac toxicity accounts for about one-half, gastrointestinal disturbances for about one-fourth, and CNS and other toxicity for about one-fourth of these adverse events.
(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Covis Pharma at 1-877-411-2510 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In general, the adverse reactions of LANOXIN are dose-dependent and occur at doses higher than those needed to achieve a therapeutic effect.
Hence, adverse reactions are less common when LANOXIN is used within the recommended dose range, is maintained within the therapeutic serum concentration range, and when there is careful attention to concurrent medications and conditions. In the DIG trial (a trial investigating the effect of digoxin on mortality and morbidity in patients with heart failure), the incidence of hospitalization for suspected digoxin toxicity was 2% in patients taking LANOXIN compared to 0.9% in patients taking placebo [see Clinical Studies (14.1)].
The overall incidence of adverse reactions with digoxin has been reported as 5-20%, with 15-20% of adverse events considered serious. Cardiac toxicity accounts for about one-half, gastrointestinal disturbances for about one-fourth, and CNS and other toxicity for about one-fourth of these adverse events. Gastrointestinal: In addition to nausea and vomiting, the use of digoxin has been associated with abdominal pain, intestinal ischemia, and hemorrhagic necrosis of the intestines.
CNS: Digoxin can cause headache, weakness, dizziness, apathy, confusion, and mental disturbances (such as anxiety, depression, delirium, and hallucination). Other: Gynecomastia has been occasionally observed following the prolonged use of digoxin. Thrombocytopenia and maculopapular rash and other skin reactions have been rarely observed.
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Experience with digoxin in pregnant women over several decades, based on published retrospective clinical studies and case reports, has not led to the identification of a drug associated risk of major birth defects, miscarriage or adverse maternal and fetal outcomes. Untreated underlying maternal conditions, such as heart failure and atrial fibrillation, during pregnancy pose a risk to the mother and fetus (see Clinical Consideration).
Animal reproduction studies have not been conducted with digoxin. The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Pregnant women with heart failure are at increased risk for preterm birth. Clinical classification of heart disease may worsen with pregnancy and lead to maternal or fetal death. Pregnant women with atrial fibrillation are at an increased risk of delivering a low birth weight infant.
Atrial fibrillation may worsen with pregnancy and can lead to maternal or fetal death. Fetal/neonatal adverse reactions Digoxin has been shown to cross the placenta and is found in amniotic fluid. Monitor neonates for signs and symptoms of digoxin toxicity, including vomiting, and cardiac arrhythmias [see Warnings and Precautions (5.3)].
Dose adjustments during pregnancy and the postpartum period LANOXIN requirements may increase during pregnancy and decrease in the postpartum period. Monitor serum digoxin levels during pregnancy and the postpartum period [see Dosage and Administration (2.5)]. Labor or Delivery Risk of arrhythmias may increase during the labor and delivery.
Monitor patients continuously during labor and delivery [see Warnings and Precautions (5.1 and 5.2)].
Mechanism of action
12.1 Mechanism of Action All of digoxin’s actions are mediated through its effects on Na-K ATPase. This enzyme, the “sodium pump,” is responsible for maintaining the intracellular milieu throughout the body by moving sodium ions out of and potassium ions into cells. By inhibiting Na-K ATPase, digoxin causes increased availability of intracellular calcium in the myocardium and conduction system, with consequent increased inotropy, increased automaticity, and reduced conduction velocity indirectly causes parasympathetic stimulation of the autonomic nervous system, with consequent effects on the sino-atrial (SA) and atrioventricular (AV) nodes reduces catecholamine reuptake at nerve terminals, rendering blood vessels more sensitive to endogenous or exogenous catecholamines increases baroreceptor sensitization, with consequent increased carotid sinus nerve activity and enhanced sympathetic withdrawal for any given increment in mean arterial pressure increases (at higher concentrations) sympathetic outflow from the central nervous system (CNS) to both cardiac and peripheral sympathetic nerves allows (at higher concentrations) progressive efflux of intracellular potassium, with consequent increase in serum potassium levels.
The cardiologic consequences of these direct and indirect effects are an increase in the force and velocity of myocardial systolic contraction (positive inotropic action), a slowing of the heart rate (negative chronotropic effect), decreased conduction velocity through the AV node, and a decrease in the degree of activation of the sympathetic nervous system and renin-angiotensin system (neurohormonal deactivating effect).
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics The times to onset of pharmacologic effect and to peak effect of preparations of LANOXIN are shown in Table 7. Table 7. Times to Onset of Pharmacologic Effect and to Peak Effect of Preparations of LANOXIN a Documented for ventricular response rate in atrial fibrillation, inotropic effects and electrocardiographic changes. b Depending upon rate of infusion.
Product Time to Onset of Effect a Time to Peak Effect a LANOXIN Tablets 0.5-2 hours 2-6 hours LANOXIN Injection/IV 5-30 minutes b 1-4 hours Hemodynamic Effects: Short- and long-term therapy with the drug increases cardiac output and lowers pulmonary artery pressure, pulmonary capillary wedge pressure, and systemic vascular resistance in patients with heart failure. These hemodynamic effects are accompanied by an increase in the left ventricular ejection fraction and a decrease in end-systolic and end-diastolic dimensions.
ECG Changes: The use of therapeutic doses of LANOXIN may cause prolongation of the PR interval and depression of the ST segment on the electrocardiogram. LANOXIN may produce false positive ST-T changes on the electrocardiogram during exercise testing. These electrophysiologic effects are not indicative of toxicity. LANOXIN does not significantly reduce heart rate during exercise.
Pharmacokinetics
The urinary metabolites, which include dihydrodigoxin, digoxigenin bisdigitoxoside, and their glucuronide and sulfate conjugates are polar in nature and are postulated to be formed via hydrolysis, oxidation, and conjugation.
Excretion: Elimination of digoxin follows first-order kinetics (that is, the quantity of digoxin eliminated at any time is proportional to the total body content).
Following intravenous administration to healthy volunteers, 50-70% of a digoxin dose is excreted unchanged in the urine.
Renal excretion of digoxin is proportional to creatinine clearance and is largely independent of urine flow.
In healthy volunteers with normal renal function, digoxin has a half-life of 1.5-2 days.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Note: The following data are from studies performed in adults, unless otherwise stated. Comparisons of the systemic availability and equivalent doses for oral preparations of LANOXIN are shown in Table 6 [see Dosage and Administration (2.6)]. Distribution: Following drug administration, a 6-8 hour tissue distribution phase is observed.
This is followed by a much more gradual decline in the serum concentration of the drug, which is dependent on the elimination of digoxin from the body. The peak height and slope of the early portion (absorption/distribution phases) of the serum concentration-time curve are dependent upon the route of administration and the absorption characteristics of the formulation.
Clinical evidence indicates that the early high serum concentrations do not reflect the concentration of digoxin at its site of action, but that with chronic use, the steady-state post-distribution serum concentrations are in equilibrium with tissue concentrations and correlate with pharmacologic effects. In individual patients, these post-distribution serum concentrations may be useful in evaluating therapeutic and toxic effects [see Dosage and Administration (2.1)].
Digoxin is concentrated in tissues and therefore has a large apparent volume of distribution (approximately 475-500 L). Digoxin crosses both the blood-brain barrier and the placenta. At delivery, the serum digoxin concentration in the newborn is similar to the serum concentration in the mother. Approximately 25% of digoxin in the plasma is bound to protein.
Serum digoxin concentrations are not significantly altered by large changes in fat tissue weight, so that its distribution space correlates best with lean (i.e., ideal) body weight, not total body weight. Metabolism: Only a small percentage (13%) of a dose of digoxin is metabolized in healthy volunteers. The urinary metabolites, which include dihydrodigoxin, digoxigenin bisdigitoxoside, and their glucuronide and sulfate conjugates are polar in nature and are postulated to be formed via hydrolysis, oxidation, and conjugation.
The metabolism of digoxin is not dependent upon the cytochrome P-450 system, and digoxin is not known to induce or inhibit the cytochrome P-450 system. Excretion: Elimination of digoxin follows first-order kinetics (that is, the quantity of digoxin eliminated at any time is proportional to the total body content). Following intravenous administration to healthy volunteers, 50-70% of a digoxin dose is excreted unchanged in the urine.
Renal excretion of digoxin is proportional to creatinine clearance and is largely independent of urine flow. In healthy volunteers with normal renal function, digoxin has a half-life of 1.5-2 days. The half-life in anuric patients is prolonged to 3.5-5 days. Digoxin is not effectively removed from the body by dialysis, exchange transfusion, or during cardiopulmonary bypass because most of the drug is bound to extravascular tissues.
Special Populations: Geriatrics: Because of age-related declines in renal function, elderly patients would be expected to eliminate digoxin more slowly than younger subjects. Elderly patients may also exhibit a lower volume of distribution of digoxin due to age-related loss of lean muscle mass. Thus, the dosage of digoxin should be carefully selected and monitored in elderly patients [see Use in Specific Populations (8.5)].
Gender: In a study of 184 patients, the clearance of digoxin was 12% lower in female than in male patients. This difference is not likely to be clinically important. Hepatic Impairment: Because only a small percentage (approximately 13%) of a dose of digoxin undergoes metabolism, hepatic impairment would not be expected to significantly alter the pharmacokinetics of digoxin.
In a small study, plasma digoxin concentration profiles in patients with acute hepatitis generally fell within the range of profiles in a group of healthy subjects. No dosage adjustments are recommended for patients with hepatic impairment; however, serum digoxin concentrations should be used, as appropriate, to help guide dosing in these patients.
Renal Impairment: Since the clearance of digoxin correlates with creatinine clearance, patients with renal impairment generally demonstrate prolonged digoxin elimination half-lives and greater exposures to digoxin. Therefore, titrate carefully in these patients based on clinical response and based on monitoring of serum digoxin concentrations, as appropriate.
Race: The impact of race differences on digoxin pharmacokinetics has not been formally studied. Because digoxin is primarily eliminated as unchanged drug via the kidney and because there are no important differences in creatinine clearance among races, pharmacokinetic differences due to race are not expected.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Digoxin 50mcg/mL, 60mL Elixir | ₱567.00–₱787.84Reference ₱567.00 | per unit | DPRI procurement range |
| Digoxin 250 mcg Tablet | ₱3.00–₱5.00Reference ₱3.97 | per tablet | DPRI procurement range |
| Digoxin 250 mcg/mL, 2 mL Ampule | ₱90.00–₱210.00Reference ₱108.34 | per ampule | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Digoxin |
| PNF listing | Oral: 250 micrograms tabletRestrictions: Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Oral: 50 micrograms/mL elixir, 60 mLRestrictions: Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 250 micrograms/mL, 2 mL ampul (IM, IV)Restrictions: Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. LANOXIN · Covis Pharma US, Inc [US FDA-approved label, version 10, October 17, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ec84cac-6ecc-43dc-8006-6ccc029e2707
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
